Skip to main content Deutsch

Publications

Last year | Last five years | All

2024 Original Articles

  • Zifko U, Guendling K, Seet R, Kasper S (2024) Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care Front. Pharmacol., 15: 1338235
    | Weblink |
  • Bartova L, Fugger G, Dold M, Kautzky A, Bairhuber I, Kloimstein P, Fanelli G, Zanardi R, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Fabbri C, Serretti A, Kasper S (2024) The clinical perspective on late-onset depression in European real-world treatment settings Int. J. Neuropsychopharmacol., 84: 59-68
    | Weblink |
  • Kasper S, Volz H, Möller H, Schläfke S, Klement S, Anghelescu I, Seifritz E (2024) Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial Eur Arch Psychiatry Clin Neurosci,
    | Weblink |
  • Oliva V, Martone A, Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, Maron E, Squassina A, Pisanu C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Baune B, Serretti A, Fabbri C, Potier M, van Westrhenen R, Rybakowski F, Mehta D, Dierssen M, Janzing J, Liò P (2024) Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression Neuroscience Applied, 3: 103937
    | Weblink |
  • Kadriu B, Deng Z, Kraus C, Johnston J, Fijtman A, Henter I, Kasper S, Zarate C (2024) The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study Bipolar Disorders, 26: 160-175
    | Weblink |

2024 Reviews

  • Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R (2024) Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data Schizophr Res, 272: 1-11
    | Weblink |

2023 Original Articles

  • Spies M, Silberbauer L, Kasper S (2023) Letter to the editor refers to “Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression” Decision making in treatment resistant depression: appeal for an individualized approach. N Engl J Med, 389 (10): 960
    | Weblink |
  • Kasper S, Eckert A, Möller H, Volz H, Seifritz E (2023) Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan Int J Psychiatry Clin Pract, 27 (3): 285-291
    | Weblink |
  • Wegener T, Edwards D, Kasper S (2023) The potential role of Rhodiola rosea L. extract WS® 1375 for patients with post-COVID-19 fatigue hb TIMES Schw Aerztej, 8 (1): 56-61
    | Weblink |
  • Buchmayer F, Kasper S (2023) Overcoming the myths of esketamine administration: different and not difficult Front Psychiatry, 14
    | Weblink |
  • Kasper S (2023) Cheers and a thank-you note from the founding chief-editor Int J Psychiatry Clin Pract, 27 (4): 319-322
    | Weblink |
  • McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly‐Uson J, Mansur R, McAllister‐Williams R, Murrough J, Nemeroff C, Nierenberg A, Rosenblat J, Sanacora G, Schatzberg A, Shelton R, Stahl S, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Maj M (2023) Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions World Psychiatry, 22 (3): 394-412
    | Weblink |
  • Kautzky A, Bartova L, Fugger G, Dold M, Souery D, Montgomery S, Zohar J, Mendlewicz J, Fabbri C, Serretti A, Rujescu D, Kasper S (2023) Age as a moderating factor of treatment resistance in depression Eur Psychiatry, 66: ahead of print
    | Weblink |
  • Dold M, Bartova L, Volz H, Seifritz E, Möller H, Schläfke S, Kasper S (2023) Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials Eur Arch Psychiatry Clin Neurosci, 273 (7): 1615-1628
    | Weblink |
  • Stöhrmann P, Godbersen G, Reed M, Unterholzner J, Klöbl M, Baldinger-Melich P, Vanicek T, Hahn A, Lanzenberger R, Kasper S, Kranz G (2023) Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: first results J Affect Disord, 324: 660-669
    | Weblink |
  • Murgaš M, Unterholzner J, Stöhrmann P, Philippe C, Godbersen G, Nics L, Reed M, Vraka C, Vanicek T, Wadsak W, Kranz G, Hahn A, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Baldinger-Melich P (2023) Effects of bilateral sequential theta-burst stimulation on 5-HT1A receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial Transl Psychiat, 13 (1)
    | Weblink |
  • Kraus C, Kautzky A, Watzal V, Gramser A, Kadriu B, Deng Z, Bartova L, Zarate C, Lanzenberger R, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fanelli G, Serretti A, Kasper S (2023) Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database J Affect Disord, 335: 349-357
    | Weblink |
  • Bartova L, Fugger G, Dold M, Kautzky A, Fanelli G, Zanardi R, Albani D, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Montgomery S, Zohar J, Fabbri C, Serretti A, Kasper S (2023) Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder J Affect Disord, 332: 105-114
    | Weblink |
  • Kasper S (2023) Fluch oder Segen von Benzodiazepinen: neu bewertet Jatros Neurologie & Psychiatrie , : 5
  • Kasper S (2023) Evidenzbasis pflanzlicher Arzneimittel in der Psychopharmakotherapie Psychopharmakotherap, 30: 11-20
  • Oliva V, Fanelli G, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Fabbri C, Serretti A (2023) Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns J Affect Disord, 320: 534-543
    | Weblink |

2023 Reviews

  • Pallanti S, Zohar J, Kasper S, Möller H, Hollander E (2023) Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach Psychiat Gen, 170: 65-72
    | Weblink |
  • Bartova L, Lanzenberger R, Rujescu D, Kasper S (2023) Reply to: “The serotonin theory of depression: a systematic umbrella review of the evidence” published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA in Molecular Psychiatry (2022 Jul 20. doi: 10.1038/s41380-022-01661-0) Mol Psychiatry, 28 (8): 3153-3154
    | Weblink |
  • Himmerich H, Lewis Y, Conti C, Mutwalli H, Karwautz A, Sjögren J, Uribe Isaza M, Tyszkiewicz-Nwafor M, Aigner M, McElroy S, Treasure J, Kasper S, Bailer U, Bulik C, Conti C, Zwaan M, Favaro A, Fernandez-Aranda F, Fetissov S, Hilbert A, Himmerich H, Wijbrand Hoek H, Kan C, Karpenko O, Karwautz A, Kasper S, Kaye W, Lewis Y, McElroy S, Mitchell J, Monteleone P, Mörkl S, Müller D, Mutwalli H, Nazar B, Papežová H, Sjögren J, Steiger H, Stein D, Szabo C, Tyszkiewicz-Nwafor M, Voderholzer U, Uribe Isaza M, Wade T, Wranik W, Yoshiuchi K, (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders World J Biol Psychiatry, 24: 643-706
    | Weblink |
  • Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S (2023) Silexan for treatment of anxiety and depression in the context of COVID-19 Eur Neuropsychopharmacol, 70: 47-48
    | Weblink |

2023 Book Chapters

  • Inada K, Yamawaki S, Kanba S, Shinozaki G, Kasper S (2023) General Principles of Pharmacologic Therapy. In: Springer Verlag, Springer Verlag Heidelberg, New York Springer Verlag, Heidelberg, New York: ahead of print
    | Weblink |

Partners and Support